[{"orgOrder":0,"company":"InflaRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INF904","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"HIBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Felzartamab","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ HIBio","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ HIBio"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Scleroderma Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Scleroderma Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Scleroderma Research Foundation"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : INF904 is an orally administered low molecular weight C5aR inhibitor which is under clinical development for the treatment of chronic spontaneous urticaria & hidradenitis suppurativa.

                          Product Name : INF904

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 20, 2024

                          Lead Product(s) : INF904

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Under the partnership, Boehringer Ingelheim will contribute an experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF to efficiently advance promising treatments for scleroderma.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Scleroderma Research Foundation

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Under the terms of the agreements, HIBio will obtain exclusive rights to develop and commercialize MOR202 (felzartamab) and MOR210 across autoimmune and inflammatory disease, with the exception of Greater China for felzartamab and Greater China and South...

                          Product Name : MOR202

                          Product Type : Antibody

                          Upfront Cash : $15.0 million

                          June 14, 2022

                          Lead Product(s) : Felzartamab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : HIBio

                          Deal Size : $1,015.0 million

                          Deal Type : Licensing Agreement

                          blank